Bayer Licenses Regional Rights to Trius Therapeutics’ Phase III Antibiotic for Serious Gram-Positive Infections
By Heather Cartwright
Pharma Deals Review: Vol 2011 Issue 8 (Table of Contents)
Published: 12 Aug-2011
DOI: 10.3833/pdr.v2011.i8.1518 ISSN: 1756-7874
Section: Licensing
Fulltext:
Abstract
Bayer Pharma has licensed exclusive rights to develop and commercialise Trius Therapeutics’ torezolid phosphate (TR-701) for acute bacterial skin and skin structure infections (aBSSSI) and pneumonia in China, Japan and all other countries in Asia, Africa, Latin America and the Middle East, excluding North and South Korea...
This page is available to subscribers only.
Not a subscriber? Join here
Already Registered? Please login using the top left purple box.
Copyright: © IQVIA 2018
RSS